Literature DB >> 2880536

Non-Hodgkin lymphoma in Jamaica and its relation to adult T-cell leukemia-lymphoma.

W N Gibbs, W S Lofters, M Campbell, B Hanchard, L LaGrenade, B Cranston, J Hendriks, E S Jaffe, C Saxinger, M Robert-Guroff.   

Abstract

Of 95 patients consecutively diagnosed with non-Hodgkin lymphoma, 52 (55%) had antibodies to human T-cell leukemia-lymphoma virus, type I. Antibody positivity was strongly associated with skin involvement, leukemia, and hypercalcemia (p less than 0.02). Two patients had systemic opportunistic infections. Neither meningeal nor lung infiltration was detected, and lymph node infiltration was diffuse in all patients. Of 36 patients who received immunophenotypic classifications, 30 had diseases that affected the T-cell system, and the cells of all tested patients with these diseases showed the helper/inducer (T4) phenotype. Twenty-seven of these thirty-six patients were found to have adult T-cell leukemia-lymphoma, and of the 27, 24 had antibodies to HTLV-I. The median duration of survival in patients with adult T-cell leukemia-lymphoma was 17 weeks, but a subgroup of 9 patients had indolent courses and a median survival of 81 weeks, which suggests that the disease has differing expression with courses that range from smoldering and indolent to acute and rapidly fatal. Hypercalcemia was the most important prognostic determinant of adult T-cell leukemia-lymphoma.

Entities:  

Mesh:

Year:  1987        PMID: 2880536     DOI: 10.7326/0003-4819-106-3-361

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas.

Authors:  T Henni; M Divine; P Gaulard; C Haioun; M Duc Dodon; M F Gourdin; L Desforges; M Goossens; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

2.  HTLV-I-associated diseases.

Authors:  P A Bunn
Journal:  West J Med       Date:  1989-05

3.  Chest HRCT findings in acute transformation of adult T-cell lymphoma/leukemia.

Authors:  Fumito Okada; Haruka Sato; Ahmad Khalid Omeri; Asami Ono; Kouhei Tokuyama; Yumiko Ando; Akira Matsumoto; Masao Ogata; Kazuhiro Kohno; Kuniko Takano; Hiromu Mori
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

Review 4.  Adult T-cell leukemia-lymphoma.

Authors:  S M Neely
Journal:  West J Med       Date:  1989-05

Review 5.  Pulmonary complications in human T-cell lymphotropic virus type 1 carriers with Sjögren's syndrome, three case reports and literature review.

Authors:  Hui Yu; Futoshi Higa; Ichiro Yamadori; Satomi Yara; Yasushi Tanimoto; Shusaku Haranaga; Masao Tateyama; Jiro Fujita; Mitsune Tanimoto; Huiping Li
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

6.  Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency.

Authors:  C Béraud; S C Sun; P Ganchi; D W Ballard; W C Greene
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

7.  Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1.

Authors:  Jill-Léa Ramassamy; Patricia Tortevoye; Balthazar Ntab; Béatrice Seve; Gabriel Carles; Dominique Gaquière; Yoann Madec; Arnaud Fontanet; Antoine Gessain
Journal:  Blood Adv       Date:  2020-05-12

8.  Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis.

Authors:  Priya Kannian; Patrick L Green
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

Review 9.  Human T-cell lymphotropic-I-associated leukemia/lymphoma.

Authors:  R S Siegel; R B Gartenhaus; T M Kuzel
Journal:  Curr Treat Options Oncol       Date:  2001-08

10.  Frequency of adult T-cell leukaemia/lymphoma and HTLV-I in Ibadan, Nigeria.

Authors:  C K Williams; S S Alexander; A Bodner; A Levine; C Saxinger; R C Gallo; W A Blattner
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.